

Minimize the use of mice in preclinical research by choosing the right mouse model

Ditte Olsen, PhD Taconic Biosciences



Confidential and Proprietary I © Taconic Biosciences

Preclinical Animal Models

How necessary are animal models for modern drug discovery?

- The success rate of new drug development from conception to new drug registration is less than 10% →lack of translation from promising preclinical findings to success in human trial valley of death
- The FDA Modernization Act 2.0 Allows Animal Trials Alternatives

FDA no longer has to require animal testing for new drugs





The principle of the 3Rs



Replacement: use of alternative methods to avoid or replace the use of animals in research

• This could include in vitro techniques, computer modeling, or using less sentient organisms.



Reduction focuses on strategies to minimize the number of animals used in experiments

- Share data also the negative!
- Using appropriate statistical analyses to reduce the number of animals needed to find meaningful results



Refinement aims to enhance animal welfare by refining procedures to minimize pain, suffering, and distress

- improving housing conditions
- using less invasive techniques for example imaging



The process of choosing the correct model

Research question/goal Outcome measurement

- Clear and precise
- One per study
- Formulate a hypothesis

- Which outcome will answer your question?
- Primary and secondary outcome
- Which methods can assess the parameters/outcome?

Model

 Should be based on research question/hypothesis and outcome measurement



What makes an animal model a good animal model?

Defining Criteria for Animal Model Validation

- Face Validity is defined as how well a model replicates the disease phenotype in humans (similarity of disease/symptoms/signs between humans and the animal model)
- Construct Validity is how well the mechanism used to induce the disease phenotype in animals
 reflects the currently understood disease etiology in humans
- **Predictive Validity** is defined as the measure of how well a model can be used to predict outcomes of the disease in humans

There is no single best model



Experimental design

- Controls:
 - Positive
 - Comparative
 - Negative
 - Vehicle
 - Sham
- Randomization
 - Physical randomization
 - Computer software
- Blinding: goal should be to be as blinded as possible
- Power analysis

No blinding or randomization increases risk of false positive...

 \rightarrow contribute to the reproducibility issues



The C57BL/6 Family Tree



Behavioral differences between C57BL/6 substrains





Rotarod picture: https://en.wikipedia.org/wiki/Rotarod_performance_test#/me dia/File:Mouse_RotaRod.png

- Altered alcohol preference and consumption
- Altered response to amphetamine
- Altered fear response





Figure adapted from Deuis JR, et al. (2017) Methods Used to Evaluate Pain Behaviors in Rodents. Front. Mol. Neurosci. doi: 10.3389/fnmol.2017.00284. Licensed under CC BY 4.0 (www.creativecommons.org/licenses/by/4.0/).



Importance of strain - Inflammatory Bowel Disease (IBD)

BALB/c vs. C57BL/6 II10-/-



A new player in the game – the microbiome

- The gut microbiome can impact
 - disease development and progression
 - drug efficacy
 - Metabolism/toxicity profile of a drug

The microbiome impacts preclinical animal studies in several ways:

- Variability in results
- Reproducibility issues
- Disease models
- Translatability to humans



Figure created with Microsoft copilot



Diabetic Gut Microbiota in NOD Mice



- Spontaneously develop diabetes over time
- Autoimmune pancreatic insulitis begins at 4 weeks of age
- Diabetes incidence and progression varies

			Phylum	Class	Order	Family	Genus
100%			Bacteroidetes	Bacteroidia	Bacteroidales	[Paraprevotellaceae]	[Prevotella]
90% -			 Bacteroidetes Bacteroidetes 	Bacteroidia	Bacteroidales	Other	Other
80% -			 Bacteroidetes Bacteroidetes 	Bacteroidia Bacteroidia	Bacteroidales Bacteroidales	Porphyromonadaceae Rikenellaceae	Parabacteroides Unclassified
70% -			 Bacteroidetes Cyanobacteria 	Bacteroidia 4C0d-2	Bacteroidales YS2	S24-7 Unclassified	Unclassified Unclassified
60% -			 Deferribacteres Firmicutes 	Deferribacteres Bacilli	Deferribacterales Lactobacillales	Deferribacteraceae Lactobacillaceae	Mucispirillum Unclassified
50% -			 Firmicutes Firmicutes 	Clostridia Clostridia	Clostridiales Clostridiales	Clostridiaceae Lachnospiraceae	Other [Ruminococcus]
40% -			 Firmicutes Firmicutes 	Clostridia Clostridia	Clostridiales Clostridiales	Lachnospiraceae Lachnospiraceae	Other Unclassified
30% -			 Firmicutes Firmicutes 	Clostridia Clostridia	Clostridiales Clostridiales	Other Ruminococcaceae	Other Oscillospira
20% -			Firmicutes	Clostridia Clostridia	Clostridiales Clostridiales	Ruminococcaceae Unclassified	Ruminococcus Unclassified
10% -			Firmicutes	Clostridia Deltaproteobacteria	Other Desulfovibrionales	Other	Other
0%	Non diabatio	Diabetic	Remaining	Denaprotoobaotona	Deserver	Doodilonbilonacouo	Decanovibrio
	Non-ulabelic	Diabelic					



Importance of knowing the limitations of your model

Importance of knowing the limitations of the model

- Phenotypes to be aware of includes
 - Vision impairment
 - Hearing loss
 - Aggression perhaps need to single house the mouse
 - Survival
- Example: Humanized immune system (HIS) mice
 - Mice engrafted with human PBMC or HSC
 - Many different models on the market
 - · One of the differences between models are the survival





Using the right model for toxicity testing

The testing of TGN1412, a CD28-specific antibody, resulted in a severe cytokine release syndrome (CRS) during its first human trial in 2006:

Preclinical Testing Limitations: conducted on animals (rodents and non-human primates), which did not predict the human response accurately due to differences in immune cells (CD28 expression on CD4 effector cells are more prominent in humans that in the animal models used)

Lack of Predictive Models: The in vitro tests using human peripheral blood mononuclear cells (PBMCs) also failed to predict the cytokine release because the conditions did not mimic the *in vivo* environment accurately.

Consequence: In humans, TGN1412 caused a massive activation of T-cells, leading to the rapid release of pro-inflammatory cytokines \rightarrow "**cytokine storm**" which is a severe and life-threatening symptoms for the trial participants.

B 100 B

Figure from: Weißmüller S, et al. (2016) TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model. PLoS ONE doi:10.1371/journal.pone.0149093. Licensed under CC BY 4.0 (www.creativecommons.org/licenses/by/4.0/).



Humanized immune system mice predicts the outcome

Problem: choosing only one sex in your study

Reduction is not always good

Zolpidem (Ambien)

- A common sleeping aid drug
- Preclinical and clinical trials predominantly involved male subjects
- Consequence: especially women reported doing things like eating, walking, making phone calls and even driving the next day without having memory of it.
- Problem: women metabolize the drug at half the rate of men → should have a lower dose

Up to 80% of mice that is used in research are males

Conclusion

- Choose animal model AFTER you have stated a clear research question and determined what the readouts should be
- Mice strains are different
- Good experimental design is crucial

There is no single best model





Thank You



Confidential and Proprietary I © Taconic Biosciences